Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

Item
http://www.wikidata.org/entity/Q37258271
A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex VivoDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryImportance of Drug Pharmacokinetics at the Site of ActionCorrelation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.Topical microbicides and HIV prevention in the female genital tractExpression and localization of p-glycoprotein, multidrug resistance protein 4, and breast cancer resistance protein in the female lower genital tract of human and pigtailed macaque.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.Modeling HIV-1 Mucosal Transmission and Prevention in Humanized Mice.Critical need for appropriate mucosal sample collection to determine relational animal pharmacokinetic-pharmacodynamic models in HIV prevention.Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.
P2860

Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

Item
http://www.wikidata.org/entity/Q37258271
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and pharmacod ...... namics (PD) in HIV prevention.
@en
Pharmacokinetics and pharmacod ...... think tank on pharmacokinetics
@nl
type
label
Pharmacokinetics and pharmacod ...... namics (PD) in HIV prevention.
@en
Pharmacokinetics and pharmacod ...... think tank on pharmacokinetics
@nl
prefLabel
Pharmacokinetics and pharmacod ...... namics (PD) in HIV prevention.
@en
Pharmacokinetics and pharmacod ...... think tank on pharmacokinetics
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Pharmacokinetics and pharmacod ...... namics (PD) in HIV prevention.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P932